This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lymphocyte Therapy in Treating Patients With Kidney Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: November 1, 1999
Last updated: December 17, 2013
Last verified: December 2005

RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body.

PURPOSE: This phase II trial is studying how well lymphocyte therapy works in treating patients with stage III or stage IV kidney cancer.

Condition Intervention Phase
Kidney Cancer Biological: aldesleukin Biological: muromonab-CD3 Biological: therapeutic autologous lymphocytes Procedure: adjuvant therapy Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Adjuvant Autolymphocyte Therapy (ALT) For Patients With Non-Metastatic Renal Cell Carcinoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Survival as measured by Kaplan-Meier method at 5 years
  • Onset of recurrence as measured by Kaplan-Meier method at 5 years
  • Safety as measured by NCI Common Toxicity Criteria at completion of study

Estimated Enrollment: 90
Study Start Date: July 1994
Detailed Description:


  • Evaluate the ability of autologous lymphocyte therapy (ALT) given as adjuvant therapy following nephrectomy and/or complete surgical resection of any metastatic disease to delay or prevent metastatic recurrence in patients with high-risk renal cell carcinoma.
  • Determine the incidence of tumor recurrence and the survival of these patients treated with this regimen.
  • Determine the toxicity/morbidity of this regimen in these patients.
  • Explore the relationship between clinical response and in vitro autologous lymphocyte characteristics, including lytic activity, cytokine production, response to cytokines, and phenotypic profile in these patients treated with this regimen.
  • Assess patient immune status before, during, and after therapy.

OUTLINE: Patients are stratified according to postnephrectomy interval (less than 3 months vs more than 3 months), extent of lymph node involvement (N1 vs N2-N3), interleukin-1 concentration in initial autologous lymphocyte culture (less than 500 pg/mL vs greater than 500 pg/mL), and prenephrectomy treatment.

Mononuclear cells are collected by apheresis on day 1 and cultured with interleukin-2 and monoclonal antibody OKT3. After cellular production, the autologous lymphocytes are reinfused over at least 30 minutes. Treatment repeats monthly for 6 months and then every 3 months for 6 months in the absence of unacceptable toxicity.

Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 5 years.

PROJECTED ACCRUAL: A total of 10-90 patients will accrued for this study within 3 years.


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically documented and completely resected stage III or stage IV renal cell carcinoma, clinically staged within 2 months prior to initiation of therapy
  • No evidence of nephrotic syndrome



  • Over 16

Performance status:

  • ECOG 0-2


  • WBC at least 3,000/mm^3
  • Granulocyte count at least 1,500/mm^3
  • Platelet count 50,000/mm3 to 500,000/mm^3
  • Hemoglobin at least 10 g/dL
  • No hematologic abnormalities


  • PT no greater than 1.5 times control
  • PTT less than 1.5 times control
  • Hepatitis B surface antigen negative


  • Creatinine no greater than 4.0 mg/dL
  • Calcium no greater than 12 mg/dL
  • No symptomatic hypercalcemia


  • No uncontrolled or severe cardiac disease, e.g.:

    • No myocardial infarction within 6 months
    • No congestive heart failure


  • HIV negative
  • No significant organ dysfunction
  • No other serious medical illness that would limit life expectancy
  • No significant CNS disease including uncontrolled or untreated psychiatric or seizure disorders
  • No uncontrolled bacterial, viral, or fungal infection
  • No active peptic or duodenal ulcer
  • Adequate peripheral venous access required
  • No prior malignancy within past 5 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix
  • Not pregnant
  • Negative pregnancy test


  • No other concurrent postnephrectomy adjuvant therapy

Biologic therapy:

  • No concurrent immunotherapy


  • No concurrent chemotherapy

Endocrine therapy:

  • More than 1 week since prior corticosteroids (except as inhalation therapy for respiratory ailments or replacement for adrenal insufficiency)
  • No concurrent therapy with the following:

    • Estrogens (except as postmenopausal replacement therapy)
    • Androgens
    • Progestins
    • Antiestrogens
    • Antiandrogens
    • LHRH analogues or antagonists
    • Other hormones


  • Not specified


  • See Disease Characteristics
  • No prior solid organ allograft
  • More than 3 weeks since major surgery, including nephrectomy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002589

United States, Wisconsin
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States, 53201-2901
Sponsors and Collaborators
National Cancer Institute (NCI)
Study Chair: John P. Hanson, MD St. Luke's Medical Center
  More Information Identifier: NCT00002589     History of Changes
Other Study ID Numbers: CDR0000063744
Study First Received: November 1, 1999
Last Updated: December 17, 2013

Keywords provided by National Cancer Institute (NCI):
stage III renal cell cancer
stage IV renal cell cancer
recurrent renal cell cancer

Additional relevant MeSH terms:
Kidney Neoplasms
Carcinoma, Renal Cell
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Immunosuppressive Agents processed this record on September 19, 2017